Mayo Clinic Cancer Center Administration's function is to facilitate the mission of the Mayo Clinic Cancer Center (MCCC) in providing administrative management and centralized services that support the Center Director, Senior Leadership, Program Leaders, Shared Resource Directors and members of the Cancer Center. Cancer Center Administration (CCA) actively participates in the planning, implementation and evaluation of programmatic and shared resource activities across MCCC's three campuses. CCA also provides administrative leadership for key MCCC initiatives including efforts to bolster minority accrual to clinical trials, address health disparities, enhance integration and optimize resource utilization and performance. Specific CCA responsibilities include: ? Financial management of all Cancer Center and CCSG funds/accounts; ? Shared resource oversight; ? Design, development and implementation of Cancer Center policies and procedures; ? Management information systems necessary to fulfill intra- and extra-institutional reporting requirements, including Standard Cancer Center Information; ? Coordination of internal funding opportunities; ? Facilitation and management of planning and evaluation activities including the MCCC's External Advisory Committee and retreats; ? Coordination of MCCC committees; ? Oversight of MCCC communications strategies; ? Coordination of MCCC activities within the framework of a 3-site, matrix center consistent with institutional policy and regulatory requirements;and ? Principal liaison between the MCCC and other Mayo Clinic research, practice, education, administration and support services units, activities and functions.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA015083-38S1
Application #
8533256
Study Section
Subcommittee G - Education (NCI)
Project Start
2012-03-01
Project End
2014-02-28
Budget Start
2012-03-01
Budget End
2013-02-28
Support Year
38
Fiscal Year
2012
Total Cost
$75,000
Indirect Cost
$27,830
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Paulus, A; Akhtar, S; Yousaf, H et al. (2017) Waldenstrom macroglobulinemia cells devoid of BTKC481S or CXCR4WHIM-like mutations acquire resistance to ibrutinib through upregulation of Bcl-2 and AKT resulting in vulnerability towards venetoclax or MK2206 treatment. Blood Cancer J 7:e565
Li, Mulin Jun; Li, Miaoxin; Liu, Zipeng et al. (2017) cepip: context-dependent epigenomic weighting for prioritization of regulatory variants and disease-associated genes. Genome Biol 18:52
Finnes, Heidi D; Chaffee, Kari G; Call, Timothy G et al. (2017) Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice. Leuk Lymphoma 58:1376-1383
Patnaik, Mrinal M; Barraco, Daniela; Lasho, Terra L et al. (2017) Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia. Am J Hematol 92:542-548
Pathangey, Latha B; McCurry, Dustin B; Gendler, Sandra J et al. (2017) Surrogate in vitro activation of innate immunity synergizes with interleukin-7 to unleash rapid antigen-driven outgrowth of CD4+ and CD8+ human peripheral blood T-cells naturally recognizing MUC1, HER2/neu and other tumor-associated antigens. Oncotarget 8:10785-10808
Russell, Stephen J; Peng, Kah-Whye (2017) Oncolytic Virotherapy: A Contest between Apples and Oranges. Mol Ther 25:1107-1116
Ertz-Archambault, Natalie; Kosiorek, Heidi; Taylor, Gretchen E et al. (2017) Association of Therapy for Autoimmune Disease With Myelodysplastic Syndromes and Acute Myeloid Leukemia. JAMA Oncol 3:936-943
Peacock, Justin G; Harmsen, William S; Link, Michael J et al. (2017) Risk of Delayed Lymph Node Metastasis in Clinically N0 Esthesioneuroblastoma. J Neurol Surg B Skull Base 78:68-74
Miyoshi, Jinsei; Toden, Shusuke; Yoshida, Kazuhiro et al. (2017) MiR-139-5p as a novel serum biomarker for recurrence and metastasis in colorectal cancer. Sci Rep 7:43393
Wu, Y; Vadgama, J V (2017) Androgen Receptor as a Potential Target for Treatment of Breast Cancer. Int J Cancer Res Mol Mech 3:

Showing the most recent 10 out of 1086 publications